Ιntroduction {#Sec1}
============

The pulmonary microvascular endothelium possesses numerous metabolic properties, many of which are catalyzed by ectoenzymes expressed on the luminal pulmonary endothelial surface \[[@CR1]\]. Angiotensin-converting enzyme (ACE) is the ectoenzyme that catalyzes the conversion of angiotensin I to angiotensin II, as well as the degradation of bradykinin, thus regulating the vascular tone. Given the strategic location of the lungs, and the extent of the pulmonary capillary endothelial surface, the pulmonary vasculature is the main site of ACE activity \[[@CR1]\].

Pulmonary capillary endothelium-bound (PCEB) ACE activity has been widely studied in animals and humans by indicator-dilution techniques and has been shown to provide a quantifiable, direct and sensitive measurement of endothelial function under normal conditions and pulmonary diseases \[[@CR1], [@CR2]\].

In acute respiratory distress syndrome (ARDS), most commonly occurring during sepsis, pulmonary capillary endothelial cells appear to be among the first lung cells to be insulted, leading to impaired metabolic functionality \[[@CR3], [@CR4]\]. In this respect, PCEB-ACE activity has been shown to decrease early during ARDS and to correlate with its severity \[[@CR5]\].

Activated protein C (APC) system dysregulation plays an important role in the pathogenesis of sepsis-associated organ dysfunction \[[@CR6]\]. In 2004, the use of recombinant human APC (rhAPC; *drotrecogin alfa* (activated); Xigris; Eli Lilly, Indianapolis, IN, USA) in patients with sepsis-induced organ failure was recommended based on the results of the PROWESS study \[[@CR7], [@CR8]\]. We hypothesized that rhAPC administration in septic patients with ARDS would improve pulmonary endothelial function, as assessed by PCEB-ACE activity indices.

It should be noted that the drug was withdrawn from the market after the negative results of the PROWESS-SHOCK study \[[@CR9]\]. However, our study on the effect of rhAPC on pulmonary endothelial function of septic patients with ARDS was performed during the period that the drug was in use in patients with sepsis-induced organ dysfunction.

Methods {#Sec2}
=======

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

The study was approved by the Evangelismos Hospital Research Ethics Committee (94/9-9-2003). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, also as revised in 2013. Ιnformed written consent was obtained from all patients' next-of-kin prior to any study procedure. Our study was conducted and completed in 2004, before the International Committee of Medical Journal Editors initiated the policy requiring investigators to deposit information about trial designs. Consequently, our study was not registered.

Study Population and Measurements {#Sec4}
---------------------------------

In 2004, 19 critically-ill septic patients with ARDS treated with rhAPC were enrolled in the study. All subjects were hospitalized in a general intensive care unit (ICU), were mechanically ventilated, and had at least two organ dysfunctions consequent to infection, one of which was sepsis-associated respiratory dysfunction. All patients suffered from severe sepsis or septic shock and, furthermore, all patients had ARDS except three who had acute lung injury, according to the respective definitions at the time of the study \[[@CR10], [@CR11]\]; based on the current definitions, they are all considered to have suffered from sepsis or septic shock and ARDS \[[@CR12], [@CR13]\]. The decision to treat with rhAPC was taken by the patients' attending physicians, in compliance with the administration criteria valid at that time \[[@CR8]\]. They all received rhAPC at 24 μg/kg/h for 96 h in a continuous IV drip. All the precautions were taken regarding the risk of bleeding before and after major or minor surgical procedures. Major bleeding events were not noticed. After the completion of the study, patients were followed up and complete clinical and laboratory data were recorded for 28 days or until their discharge from the ICU. At the end of the study, the subjects were grouped according to their outcome (28 days survival or prior discharge from the ICU) into survivors and non-survivors.

PCEB-ACE activity was measured prior to initiation of rhAPC treatment (measurement \#1 at baseline), during the 96-h infusion (measurement \#2 at 24 h; measurement \#3 at 48 h; measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5, day 7). No patient was under ACE inhibitors. Each patient's baseline measurement served as control of him/herself.

A detailed description of the methodology used is given elsewhere \[[@CR2]\]. Trace amounts of the radiolabelled synthetic ACE substrate ^3^\[H\] benzoyl-Phe-Ala-Pro (BPAP) were injected as a rapid bolus into a (jugular or subclavian) central vein, and arterial blood was withdrawn into a fraction collector for analysis.

Single transpulmonary pass substrate utilization is expressed as percent metabolism (%*M*) and transpulmonary hydrolysis (*v* = \[*E*\] × *t*~c~ × *k*~cat~/*K*~m~), where \[*E*\] equals the enzyme concentration available for reaction, *t*~c~ the capillary transit time, *k*~cat~ the catalytic rate constant, and *K*~m~ the Michaelis--Menten constant. Functional capillary surface area (FCSA) was additionally calculated as hydrolysis × pulmonary plasma flow and depends on the total enzyme mass that is available for reaction, and the constants *k*~cat~ and *K*~m~. Both *v* and %*M* are indices that reflect ACE activity per capillary, while FCSA is a reflection of ACE activity per vascular bed \[[@CR1], [@CR2], [@CR14]\].

Statistical Analysis {#Sec5}
--------------------

Data are presented as mean ± SE, or median (interquartile range) when data distribution was skewed. Comparisons between groups were made by Student's *t* test or Mann--Whitney test, when appropriate, for continuous data, and Chi square test for qualitative data. Differences within time were examined by the Friedman test. Mixed effect models were fitted to examine the effect of time, outcome and their interaction. The Tukey--Kramer test was used for multiple comparisons adjustment. All *p* values are two-sided. Differences were considered significant at *p* \< 0.05.

Results {#Sec6}
=======

Characteristics of the Study Population {#Sec7}
---------------------------------------

Patient baseline demographic and clinical data are shown in Table [1](#Tab1){ref-type="table"}. Patients were grouped according to their clinical outcome (28 days survival) as survivors (*n* = 9) and non-survivors (*n* = 10). There were no statistically significant differences between the two groups in baseline characteristics.Table 1Demographic and clinical data of the 19 patients enrolled in the studyAll patients (19)Survivors (9)Non-survivors (10)*P* valueAge (years), mean ± SE64 ± 3.361.8 ± 4.966.3 ± 4.50.503Male sex, *n* (%)15 (79)7 (78)8 (80)0.906Days in ICU, median (IQR)4 (2--8)3 (1.5--6)6 (2.75--17)0.09Days on MV, median (IQR)4 (2--9)3 (1.5--6)6 (2.75--11.75)0.119Cause of ARDS, *n* (%)0.809Direct9 (47)4 (44)5 (50)Indirect10 (53)5 (66)5 (50)Data are expressed as number of patients (*n*), mean ± SE, or median (25--75% interquartile range)*ARDS* acute respiratory distress syndrome, *ICU* intensive care unit, *IQR* interquartile range, *MV* mechanical ventilation

The Effect of Recombinant Human APC on Pulmonary Endothelial ACE Activity and FCSA {#Sec8}
----------------------------------------------------------------------------------

In all patients, BPAP  %*M* did not significantly change during the study period: from 26.4 ± 2.6% (baseline) to 24.4 ± 2.9% at the end of the 96-h rhAPC infusion, and to 22.5 ± 2.8 at the end of the 7 days study (Fig. [1](#Fig1){ref-type="fig"}a; *p* = 0.541). In a similar pattern a non-significant fluctuation of hydrolysis (*v*) was observed in all patients from 0.32 ± 0.04 at baseline to 0.29 ± 0.04 at day 4 and to 0.27 ± 0.04 at day 7 (Fig. [1](#Fig1){ref-type="fig"}b; *p* = 0.641). FCSA at baseline was 1550 ± 212 ml/min, while similar values were obtained at day 4 (1549 ± 276 ml/min) and at day 7 (1561 ± 292 ml/min) (Fig. [1](#Fig1){ref-type="fig"}c; *p* = 0.652).Fig. 1The effect of recombinant human APC on pulmonary endothelial ACE activity and FCSA. PCEB-ACE activity was measured prior to initiation of treatment with rhAPC (measurement \#1 at baseline, *Bl*), during the 96 h infusion (measurement \#2 at 24 h, measurement \#3 at 48 h, measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5 at day 7). Substrate (BPAP) percent metabolism (%*M*) (**a**), BPAP hydrolysis (*v*) (**b**) and functional capillary surface area (FCSA) (**c**) were estimated in all patients over time. Data are presented as mean ± SE. The Friedman test was used, *p* \> 0.05. *BPAP* ^3^\[H\] benzoyl-Phe-Ala-Pro, *FCSA* functional capillary surface area, *PCEB-ACE* pulmonary capillary endothelium-bound angiotensin converting enzyme, *rhAPC* recombinant human activated protein C

PCEB-ACE Activity and Outcome (28 Days Survival) {#Sec9}
------------------------------------------------

Neither %*M* nor hydrolysis changed significantly with time in either group. In survivors, BPAP %*M* tended to decrease from 32.7 ± 3.4% at baseline to 25.6 ± 2.9% at day 7, and in non-survivors from 20.8 ± 2.8% at baseline to 15.5 ± 5% at day 7. Likewise, *v* tended to decrease from 0.41 ± 0.06 at baseline to 0.30 ± 0.04 at day 7 in survivors, and 0.24 ± 0.04 to 0.18 ± 0.06 in non-survivors (Fig. [2](#Fig2){ref-type="fig"}a, b; *p* = 0.489 and *p* = 0.499, respectively). Nonetheless, ACE substrate utilization was significantly lower in non-survivors as compared to survivors (Fig. [2](#Fig2){ref-type="fig"}a, b; *p* = 0.044 and *p* = 0.049).Fig. 2PCEB-ACE activity and outcome (28-day survival). PCEB-ACE activity was measured prior to initiation of treatment with rhAPC (measurement \#1 at baseline, *Bl*), during the 96-h infusion (measurement \#2 at 24 h, measurement \#3 at 48 h, measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5 at day 7). Patients were grouped according to their clinical outcome (28-day survival) as survivors (*n* = 9) and non-survivors (*n* = 10). Substrate (BPAP) percent metabolism (%*M*) (**a**), BPAP hydrolysis (*v*) (**b**) and functional capillary surface area (FCSA) (**c**) were estimated in all patients with time. Data are presented as mean ± SE. The mixed effect model was used, \**p* \< 0.05. *BPAP* ^3^\[H\] benzoyl-Phe-Ala-Pro, *FCSA* functional capillary surface area, *PCEB-ACE* pulmonary capillary endothelium-bound angiotensin converting enzyme, *rhAPC* recombinant human activated protein C

Functional Capillary Surface Area and Outcome (28-day Survival) {#Sec10}
---------------------------------------------------------------

FCSA increased slightly, from 1760 ± 327 ml/min at baseline to 1890 ± 338 ml/min at day 7 in survivors, while in the non-survivors FCSA dropped from 1362 ± 276 to 821 ± 402 ml/min. It tended to be higher in survivors, without, however, reaching significance (Fig. [2](#Fig2){ref-type="fig"}c, *p* = 0.075). It should be noted that the obtained values might be influenced by differences in cardiac output per patient, observed during the study (data not shown), since they affect FCSA measurements (see "[Methods](#Sec2){ref-type="sec"}").

Disease Severity and Lung Injury Scores {#Sec11}
---------------------------------------

Patients' PO~2~/FiO~2~ did not significantly change with time (Fig. [3](#Fig3){ref-type="fig"}a; *p* = 0.458). However, when patients were divided into survivors and non-survivors, the former revealed significantly higher values than the latter (Fig. [3](#Fig3){ref-type="fig"}b; *p* = 0.032). Similar patterns were observed for lung injury scores (LIS) (Fig. [3](#Fig3){ref-type="fig"}c; *p* = 0.726). Again, survivors had significantly lower LIS than non-survivors (Fig. [3](#Fig3){ref-type="fig"}d; *p* = 0.025). SOFA scores decreased with time in all patients (Fig. [4](#Fig4){ref-type="fig"}a; *p* = 0.007). The same pattern (i.e. decrease with time) was observed in both survivors and non-survivors, and were lower in survivors than in non-survivors (Fig. [4](#Fig4){ref-type="fig"}b; *p* = 0.001 and *p* = 0.04, respectively). Patients' APACHE II scores also decreased with time in all patients (Fig. [4](#Fig4){ref-type="fig"}c; *p* = 0.033). The same pattern (i.e. decrease with time) was observed in both survivors and non-survivors (Fig. [4](#Fig4){ref-type="fig"}d; *p* = 0.045). However no differences were noted between the two groups (Fig. [4](#Fig4){ref-type="fig"}d; *p* = 0.189).Fig. 3Lung disease severity scores (PO~2~/FiO~2~ and LIS). PO~2~/FiO~2~was measured prior to initiation of treatment with rhAPC (measurement \#1 at baseline, *Bl*), during the 96-h infusion (measurement \#2 at 24 h, measurement \#3 at 48 h, measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5 at day 7). Results are given for the whole cohort (**a**) and for survivors versus non-survivors (**b**). Lung injury scores (*LIS*) were measured prior to initiation of treatment with rhAPC (measurement \#1 at baseline, *Bl*), during the 96-h infusion (measurement \#2 at 24 h, measurement \#3 at 48 h, measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5 at day 7). Results are given for the whole cohort (**c**) and for survivors versus non-survivors (**d**). Data are presented as mean ± SE. **a**, **c** The Friedman test was used, *p* \> 0.05. **b**, **d** The mixed effect model was used, \**p* \< 0.05. *rhAPC* recombinant human activated protein C Fig. 4Disease severity scores. SOFA scores were measured in all patients prior to initiation of treatment with rhAPC (measurement \#1 at baseline, *Bl*), during the 96-h infusion (measurement \#2 at 24 h, measurement \#3 at 48 h, measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5 at day 7). Results are given for the whole cohort (**a**) and for survivors versus non-survivors (**b**). APACHE II scores were measured in all patients prior to initiation of treatment with rhAPC (measurement \#1 at baseline, *Bl*), during the 96-h infusion (measurement \#2 at 24 h, measurement \#3 at 48 h, measurement \#4 at 96 h) and 3 days after the end of the rhAPC infusion (measurement \#5 at day 7). Results are given for the whole cohort (**c**) and for survivors versus non-survivors (**d**). Data are presented as mean ± SE. **a**, **c** The Friedman test was used, ^\#^*p* \< 0.05 with time. **b**, **d** The mixed effect model was used, ^\#^*p* \< 0.05 with time and \**p* \< 0.05 between groups. *APACHE* Acute physiology and chronic health evaluation, *rhAPC* recombinant human activated protein C, *SOFA* sequential organ failure assessment

It is worth mentioning that PCEB-ACE activity indices were the only significantly different parameters between survivors and non-survivors at baseline; no other disease or lung injury severity score was significantly different at baseline (data not shown). More specifically, in survivors, BPAP %*M* at baseline was 32.7 ± 3.4% compared to 20.8 ± 2.8% in non-survivors (Mann--Whitney, *p* = 0.017). Baseline hydrolysis (*v*) was 0.41 ± 0.06 in survivors and 0.24 ± 0.04 in non-survivors (Mann--Whitney, *p* = 0.017).

Discussion {#Sec12}
==========

In sepsis, the dysregulated interaction between inflammation and coagulation underlies organ dysfunction \[[@CR6]\]. On this basis, it was suggested that natural anticoagulants, that are down-regulated in sepsis, could be used as a salvage therapy in septic organ failure. Recombinant human APC was the only anticoagulant initially shown to be effective in decreasing mortality in severely septic patients \[[@CR7]\]. Furthermore, several experimental studies have documented the beneficial effects of the treatment with rhAPC (intravenous or inhaled) on inflammation-induced lung injury \[[@CR15]--[@CR19]\].

Pulmonary capillary ACE activity has been proved to be a reliable index of endothelial dysfunction in variable pulmonary diseases \[[@CR1], [@CR5], [@CR20]\]. Contrary to other surrogate markers of endothelial injury, such as circulating adhesion molecules and other soluble endothelial-derived proteins, its measurement by means of indicator-dilution type techniques provides a direct and sensitive quantification of pulmonary endothelial function at the patients' bedside. Both substrate transpulmonary hydrolysis (*v*) and FCSA have been shown to decrease early during the ARDS continuum and to be inversely related to LIS \[[@CR5]\].

In this study we evaluated baseline PCEB-ACE activity in a homogenous, septic population with ARDS, in the sense that they all fulfilled the criteria for rhAPC administration. We rationalized that a beneficial effect of rhAPC on pulmonary microcirculation would be depicted as an amelioration of the PCEB-ACE activity indices. Our hypothesis was not confirmed: rhAPC treatment had no significant effect on pulmonary endothelial function as estimated by this method. Our results coincided with the uncertainty that emerged about the efficacy and the concerns regarding the use of rhAPC in the treatment of sepsis. The PROWESS-SHOCK study that was conducted for the re-examination of the risk/benefit profile of rhAPC failed to document a mortality benefit \[[@CR9]\], leading to the withdrawal of the product from the market. Despite rhAPC withdrawal, related research has been recently published, driving us to present these previously obtained data. In this context, a study using the pulmonary leak index of 67Gallium transferrin technique to measure alveolo-capillary permeability in patients with ARDS treated with rhAPC also failed to reveal a beneficial effect of the treatment \[[@CR21]\].

In our study population, the estimated BPAP percent metabolism and hydrolysis were considerably decreased compared to the values of normal volunteers with no lung pathologies \[[@CR1], [@CR2], [@CR22]\]. Further analysis of our results attempted to examine a possible relation of PCEB-ACE activity with patient outcome. Indeed, poor outcome (defined as mortality) was associated with more prominent pulmonary capillary endothelial dysfunction, as expressed by the significantly lower values of PCEB-ACE activity indices (i.e. %*M* and *v*). These results were in accordance with the estimations of disease and respiratory severity indices and scores: when mixed effect models were fitted, non-survivors were found to express worse PO~2~/FiO~2~, as well as LIS and SOFA scores. However, it is worth mentioning that the values of %*M* and hydrolysis (*v*) were statistically lower in the non-survivors group from the very first measurement (baseline measurement) compared to survivors, in contrast to all other measured disease severity indices, which showed no significant difference between the two groups at baseline (data not shown). This may denote a superiority of the PCEB-ACE activity indices in providing early information on outcome.

Τhe complex pathophysiology of sepsis and the heterogeneity of septic patients are perhaps reasons why clinicians are still lacking specific treatment options for this syndrome. Our study population consisted of septic patients with ARDS and similar clinical severity, with the limitation of the small size. Nevertheless, our results support a potential implementation of direct markers of endothelial dysfunction in everyday clinical practice. Such markers accompanied by clinical severity scores and other surrogate indices might serve the need for better risk stratification and personalized treatment in sepsis.

Conclusion {#Sec13}
==========

In our cohort of septic patients with ARDS, pulmonary endothelium ACE activity was severely impaired, denoting pulmonary endothelial dysfunction. Our results showed that rhAPC treatment had no effect on pulmonary endothelium function. However, we were able to demonstrate that PCEB-ACE activity indices quantitatively expressed the endothelial pathophysiology that underlies sepsis-associated ARDS. Furthermore, they seem to represent early and possibly more sensitive markers of outcome compared to other well-established clinical severity indices and scores. It should be noted that the indicator-dilution techniques are arduous procedures, not easily performed in the everyday clinical practice. Future studies using "less demanding" techniques at the bedside are needed in an effort to develop clinically useful tests \[[@CR23]\].
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